Antibodies against human CEACAM1 – Monoclonal antibodies for the detection of A1/B-domains of the cancer-implicated adhesion-rec

The present invention relates to antibodies that exhibit a high affinity and specificity for the A1/B-domains of CEACAM1.

Commercial Opportunities CEACAM1 is an adhesion receptor molecule implicated in growth regulation and the development of cancer. It belongs to the family of carcinoembryonic antigens which forms a part of the immunoglobulin superfamily (IgSF). CEACAMs play a central role with respect to cell adhesion, differentiation, activation, proliferation, morphogenesis and apoptosis as well as receptors for various pathogens (e. g. bacteria). CEACAMs are structurally closely related: they feature the function triggering N-domain and a C-domain consisting of A- and B-domains. Due to the structural similarity it is very challenging to obtain antibodies against specific CEACAM1-domains. CEACAM1 has been detected at elevated levels in the surrounding tissue of tumors and the tumors themselves. It appears that CEACAM1 is a suitable biomarker for the diagnosis and staging of tumors. The present invention relates to antibodies that exhibit a high affinity and mono-specificity for the A1/B-domains of human CEACAM1. Thus, they are suitable to detect the membrane anchored, the cleaved soluble CEACAM1 and most of its derivatives and may be used in various in-vitro techniques in cancer research, e.g. ELISA, WB, IHC, fluorescence microscopy and flow cytometry.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert